868,160 Shares of Kailera Therapeutics, Inc. $KLRA Acquired by State Street Corp

Key Points

• State Street Corp acquired 868,160 shares of Kailera Therapeutics in the second quarter, worth approximately $19.1 million and representing about 0.67% of the company. Several other institutional investors also initiated positions, including Atlas Venture and Wellington Management.
• Kailera shares opened at $11.22, near their 52-week low of $11.10 and well below the 50-day moving average of $16.35. The company reported a quarterly loss of $1.09 per share, missing analysts’ estimate of $0.74.
• Analyst sentiment remains mixed, with recent sell ratings offset by broader optimism: Kailera has a consensus “Moderate Buy” rating and a $42.75 price target, despite its investigational obesity drug pipeline and projected full-year loss.

State Street Corp acquired a new position in Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 868,160 shares of the company's stock, valued at approximately $19,126,000. State Street Corp owned about 0.67% of Kailera Therapeutics at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Tidal Investments LLC purchased a new stake in shares of Kailera Therapeutics during the second quarter valued at $309,000. Squarepoint Ops LLC bought a new position in Kailera Therapeutics in the second quarter worth approximately $993,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics during the 2nd quarter worth $24,233,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics during the 2nd quarter valued at $64,308,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Kailera Therapeutics in the 2nd quarter worth $113,923,000.

Kailera Therapeutics Price Performance

Shares of NASDAQ KLRA opened at $11.22 on Friday. The stock has a market capitalization of $1.45 billion and a P/E ratio of -0.00. The business's fifty day moving average price is $16.35. Kailera Therapeutics, Inc. has a 1 year low of $11.10 and a 1 year high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). As a group, equities analysts predict that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Weiss Ratings began coverage on Kailera Therapeutics in a research note on Friday, August 14th. They set a "sell (d)" rating on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $42.75.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

Want to see what other hedge funds are holding KLRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.